SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 20, 2003; DOI 10.1182/blood-2002-12-3674. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-12-3674v1 102/2/477    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhou, P. Articles by Comenzo, R. L. Search for Related Content PubMed PubMed Citation Articles by Zhou, P. Articles by Comenzo, R. L. Related Collections Transplantation Brief Reports Clinical Trials and Observations Hematopoiesis and Stem Cells Neoplasia Transfusion Medicine Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 July 2003, Vol. 102, No. 2, pp. 477-479 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination Ping Zhou, Yana Zhang, Carmen Martinez, Nagesh Kalakonda, Stephen D. Nimer, and Raymond L. Comenzo From the Hematology Service, Division of Hematologic Oncology, Department of Medicine, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY. Optimal methods of stem cell mobilization in multiple myeloma are undefined, and contaminating clonotypic cells could contribute to disease recurrence. A phase 2 trial of intravenous melphalan (60 mg/m2) and granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/d) for mobilization was performed. To enhance reliability, contamination was assessed with 2 sensitive methods, immunoglobulin light and heavy chain variable region patient-specific limiting-dilution polymerase chain reaction (PCR). We evaluated 29 stem cell components (SCCs) from 15 patients; for 9 SCCs, only VL PCR was used because of light chain disease or technical problems with VH primers. For 20 SCCs, VL and VH PCR results were highly correlated (r2 = 0.93, P < .01), with 35% (7 of 20) having identical estimates. VH PCR gave significantly higher estimates for 8—and VL PCR for 5—SCCs, supporting the utility of using 2 methods. Estimated clonotypic contamination per SCC was 0.0009% (range, 0%-0.1%) or 0.5 x 104 clonotypic cells per kilogram (range, 0-41.2 x 104/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P < .01). Melphalan-mobilized SCCs contain minimal clonotypic contamination. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. L. Comenzo, P. Zhou, M. Fleisher, B. Clark, and J. Teruya-Feldstein Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins Blood, May 1, 2006; 107(9): 3489 - 3491. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020